Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways.
Asthma
/ drug therapy
Bronchoconstriction
/ drug effects
Bronchodilator Agents
/ pharmacology
Cyclic GMP
/ metabolism
Humans
Muscle Contraction
/ drug effects
Muscle Relaxation
/ drug effects
Muscle, Smooth
/ drug effects
Nitric Oxide
/ metabolism
Respiratory System
/ drug effects
Signal Transduction
/ drug effects
Soluble Guanylyl Cyclase
/ metabolism
Trachea
/ drug effects
asthma
relaxation
remodeling
smooth muscle
Journal
American journal of respiratory cell and molecular biology
ISSN: 1535-4989
Titre abrégé: Am J Respir Cell Mol Biol
Pays: United States
ID NLM: 8917225
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
25
7
2019
medline:
12
5
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
The soluble guanylyl cyclase (sGC)-cyclic guanosine monophosphate signaling pathway evokes vascular smooth muscle relaxation; whether this pathway mediates airway smooth muscle relaxation remains controversial. We posit that sGC activators are equi-effective as β-agonists in reversing contractile agonist-induced airway smooth muscle shortening. To provide clarity, we tested the efficacy of sGC stimulator and activator drugs, BAY 41-2272 and BAY 60-2270, respectively, in reversing bronchoconstriction of human small airways using human precision-cut lung slices (hPCLS). Both BAY drugs reversed carbachol-induced bronchoconstriction to a maximal degree comparable to that of formoterol. Moreover, the sGC drugs remained effective bronchodilators despite formoterol-induced desensitization of the airways. Analysis of the hPCLS after their activation by sGC or β
Identifiants
pubmed: 31340135
doi: 10.1165/rcmb.2019-0001OC
pmc: PMC6938135
doi:
Substances chimiques
Bronchodilator Agents
0
Nitric Oxide
31C4KY9ESH
Soluble Guanylyl Cyclase
EC 4.6.1.2
Cyclic GMP
H2D2X058MU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-48Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL103453
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL114471
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Br J Pharmacol. 2016 Sep;173(18):2726-38
pubmed: 27352269
Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):665-70
pubmed: 23649864
Curr Pharm Des. 2015;21(3):274-90
pubmed: 25159070
Nitric Oxide. 2018 Jul 1;77:88-95
pubmed: 29738821
J Gen Physiol. 2010 Mar;135(3):247-59
pubmed: 20176853
Am J Respir Cell Mol Biol. 2010 Aug;43(2):179-91
pubmed: 19767449
J Cardiovasc Dev Dis. 2018 Jan 19;5(1):null
pubmed: 29367582
NPJ Syst Biol Appl. 2018 Feb 5;4:8
pubmed: 29423274
Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L179-84
pubmed: 16143586
Am J Physiol Lung Cell Mol Physiol. 2009 Sep;297(3):L530-7
pubmed: 19542247
J Clin Invest. 2006 Sep;116(9):2552-61
pubmed: 16955146
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2355-62
pubmed: 27071111
Am J Respir Cell Mol Biol. 2014 Apr;50(4):678-83
pubmed: 24219573
ChemMedChem. 2009 May;4(5):853-65
pubmed: 19263460
Pharmacol Rev. 2000 Sep;52(3):375-414
pubmed: 10977868
J Pharmacol Exp Ther. 1997 Mar;280(3):1215-8
pubmed: 9067306
Front Physiol. 2017 Aug 23;8:607
pubmed: 28878687
Br J Pharmacol. 2006 Jan;147 Suppl 1:S193-201
pubmed: 16402104
J Recept Signal Transduct Res. 2010 Feb;30(1):10-23
pubmed: 19911949
Am J Respir Crit Care Med. 1996 Feb;153(2):747-51
pubmed: 8564128
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1702-4
pubmed: 7952636
Arch Int Pharmacodyn Ther. 1995 Jan-Feb;329(1):81-96
pubmed: 7639622
Am J Respir Cell Mol Biol. 2010 Mar;42(3):373-81
pubmed: 19502388
J Allergy Clin Immunol. 2008 Oct;122(4):734-740
pubmed: 18774166
Pulm Pharmacol Ther. 2016 Dec;41:86-95
pubmed: 27816773
Am J Respir Crit Care Med. 1996 Jan;153(1):128-35
pubmed: 8542105
Circulation. 2011 May 24;123(20):2263-73
pubmed: 21606405
Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1474-8
pubmed: 7903023
Annu Rev Biochem. 2012;81:533-59
pubmed: 22404633